News articles about Selecta Biosciences (NASDAQ:SELB) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Selecta Biosciences earned a news impact score of 0.08 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.9821833508124 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of research analysts have recently commented on the company. Canaccord Genuity set a $25.00 price target on Selecta Biosciences and gave the company a “buy” rating in a research note on Friday, August 11th. UBS lowered Selecta Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. Zacks Investment Research raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th. Finally, ValuEngine lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $23.50.
Shares of Selecta Biosciences (NASDAQ SELB) traded up $0.14 during trading hours on Friday, reaching $10.06. The company had a trading volume of 228,974 shares, compared to its average volume of 301,000. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48. Selecta Biosciences has a twelve month low of $8.70 and a twelve month high of $24.02.
In related news, CFO David Siewers sold 16,424 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total transaction of $328,480.00. Following the completion of the transaction, the chief financial officer now directly owns 2,194 shares of the company’s stock, valued at approximately $43,880. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Timothy A. Springer purchased 57,598 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were acquired at an average price of $9.27 per share, with a total value of $533,933.46. Following the completion of the acquisition, the director now owns 461,349 shares in the company, valued at approximately $4,276,705.23. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 90,098 shares of company stock valued at $843,933 and have sold 355,658 shares valued at $6,955,732. 41.90% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Selecta Biosciences (SELB) Share Price” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/12/09/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-selecta-biosciences-selb-share-price.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.